Xencor, Inc.
Symbol: XNCR (NASDAQ)
10.42
▲ (0.88%) 0.091
Company Description:
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Key Stats
- Today's Open: $10.345
- Today's High: $10.47
- Today's Low: $10.345
- Today's Volume: 13.04K
- Yesterday Close: $10.33
- Yesterday High: $10.48
- Yesterday Low: $10.24
- Yesterday Volume: 428.71K
- Last Min Volume: 13.04K
- Last Min High: $10.462
- Last Min Low: $10.421
- Last Min VWAP: $10.462
Company Profile
- Name: Xencor, Inc.
- Website: https://www.xencor.com
- Listed Date: 2013-12-03
- Location: PASADENA, CA
- Market Status: Active
- CIK Number: 0001326732
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $736.77M
- Round Lot: 100
- Outstanding Shares: 71.32M
- Asset Type: CS
RECENT FILINGS FOR XNCR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 3 | View |
| 2025-07-31 | 8-K | View |
| 2025-07-29 | SCHEDULE 13G/A | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 144 | View |
| 2025-06-16 | 144 | View |
| 2025-06-16 | 144 | View |
| 2025-06-16 | 144 | View |
| 2025-06-16 | 144 | View |
| 2025-06-13 | 8-K | View |
Latest News on XNCR